Posted on 03/11/2009 in Pharmaceutical Company Product News Eisai has revealed that a trial into its metastatic breast cancer treatment E7389 (eribulin mesylate) achieved its primary endpoint.
As part of the study, doctors administered either eribulin or one treatment of their choice, including single agent chemotherapy, hormonal treatment or biological therapy, to 762 women with the disease.
Eribulin was administered intravenously over two to five minutes on days one and eight every 21 days.
The trial demonstrated noticeable improvement in overall survival among those receiving eribulin, compared with the physician's choice of therapy.
Eisai now plans to submit a marketing authorisation application for the product in those patients with both locally advanced and metastatic breast cancer.
In other Eisai news, the firm entered into a partnership with Quintiles this week, which will see the two firms jointly develop six new anti-cancer drugs.
These compounds are eribulin mesylate (E7389), E7080, Ontak (denileukin diftitox), E7820, E6201 and E7050, the companies revealed.
Other news stories from 03/11/2009
Read more in the Zenopa News Archive
How this news is generated
|
